Pharmaceutical exports from India recorded a steady growth of 5.6% in FY2025–26, reflecting sustained global demand for affordable generic medicines and the country’s strong manufacturing capabilities.
The growth was driven by robust shipments to key markets including the United States, Europe, and emerging economies, where Indian drugmakers continue to play a critical role in supplying cost-effective treatments. Increased demand for chronic therapies, vaccines, and specialty drugs also contributed to the upward trend.
Industry stakeholders highlighted that regulatory compliance, improved quality standards, and diversification into complex generics and biosimilars have strengthened India’s position as a global pharmaceutical hub. Government initiatives aimed at boosting domestic manufacturing and exports further supported the sector’s performance during the fiscal year.
However, exporters continue to face challenges such as pricing pressures in regulated markets, evolving compliance requirements, and supply chain disruptions linked to geopolitical tensions. Currency fluctuations and rising input costs have also impacted margins for some companies.
Despite these headwinds, the outlook for India’s pharmaceutical exports remains positive, with industry experts expecting continued growth driven by innovation, market expansion, and increasing global reliance on Indian medicines.